Revvity Somatostatin, Tyr11, 50µci

Revvity 50 µCi Quantities of Somatostatin, [¹²⁵I]Tyr¹¹ are available for your research. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer radioligands and radiolabeled biomolecules to use as tracers, for radioimmunoassays (RIAs), for autoradiographic visualization, or for performing saturation and competition radioligand binding assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radiolabeled compounds is fully characterized for pharmacological action and validated in binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiochemicals remain the most sensitive method for probing binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NEX389: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Sparre-Ulrich, A.H., Gabe, M.N., Gasbjerg, L.S., Christiansen, C.B., Svendsen, B., Hartmann, B., Holst, J.J., Rosenkilde, M.M. (2017), GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem Pharmacol, 131: 78-88.Sparre-Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., and Rosenkilde, M. M. (2016) Species-specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 173: 27–38.